Loud applause erupted when an advisory panel recommended in early June that the US Food and Drug Administration (FDA) approve the first medication to treat low libido in women. Many more must have cheered when the FDA followed the committee’s advice and approved the prescription drug, which will go by the name Addyi, on 18 August.